Curis (CRIS) to Release Quarterly Earnings on Wednesday

Curis (NASDAQ:CRIS) is expected to be issuing its results before the market opens on Wednesday, February 4th. Analysts expect the company to announce earnings of ($0.4325) per share and revenue of $3.2490 million for the quarter.

Curis (NASDAQ:CRIS) last announced its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.13. The company had revenue of $3.18 million during the quarter, compared to analyst estimates of $2.86 million. On average, analysts expect Curis to post $-7 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Curis Stock Performance

Shares of CRIS opened at $0.95 on Wednesday. The company has a 50-day simple moving average of $1.09 and a 200-day simple moving average of $1.44. The firm has a market capitalization of $12.28 million, a P/E ratio of -0.26 and a beta of 3.00. Curis has a 52 week low of $0.77 and a 52 week high of $3.57.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Curis in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Curis has an average rating of “Hold” and a consensus price target of $17.00.

Institutional Trading of Curis

Hedge funds and other institutional investors have recently modified their holdings of the company. Armistice Capital LLC lifted its position in shares of Curis by 8.7% in the third quarter. Armistice Capital LLC now owns 978,190 shares of the biotechnology company’s stock worth $1,624,000 after purchasing an additional 78,265 shares in the last quarter. Maverick Capital Ltd. boosted its holdings in shares of Curis by 7.8% during the second quarter. Maverick Capital Ltd. now owns 681,381 shares of the biotechnology company’s stock worth $1,472,000 after acquiring an additional 49,554 shares during the period. Finally, Squarepoint Ops LLC raised its position in shares of Curis by 17.9% in the third quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock valued at $98,000 after buying an additional 8,973 shares in the last quarter. Institutional investors and hedge funds own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.